ScreenIT

Latest preprint reviews

1. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

   This article has 13 authors:

   1. Hiroshi Mukae
   2. Hiroshi Yotsuyanagi
   3. Norio Ohmagari
   4. Yohei Doi
   5. Takumi Imamura
   6. Takuhiro Sonoyama
   7. Takahiro Fukuhara
   8. Genki Ichihashi
   9. Takao Sanaki
   10. Keiko Baba
   11. Yosuke Takeda
   12. Yuko Tsuge
   13. Takeki Uehara

   Reviewed by ScreenIT

2. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave

   This article has 6 authors:

   1. Ayman Al Jurdi
   2. Leela Morena
   3. Mariesa Cote
   4. Emily Bethea
   5. Jamil Azzi
   6. Leonardo V. Riella

   Reviewed by ScreenIT

3. Unmet Dental Needs in Children Following Suspension of School‐Based Oral Health Services Due to COVID ‐19

   This article has 6 authors:

   1. Ryan R. Ruff
   2. Tamarinda J. Barry Godín
   3. Rachel Whittemore
   4. Topaz Murray Small
   5. Nydia Santiago‐Galvin
   6. Priyanka Sharma

   Reviewed by ScreenIT

4. Multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS

   This article has 17 authors:

   1. Richa Batra
   2. William Whalen
   3. Sergio Alvarez-Mulett
   4. Luis G. Gomez-Escobar
   5. Katherine L. Hoffman
   6. Will Simmons
   7. John Harrington
   8. Kelsey Chetnik
   9. Mustafa Buyukozkan
   10. Elisa Benedetti
   11. Mary E. Choi
   12. Karsten Suhre
   13. Edward Schenck
   14. Augustine M. K. Choi
   15. Frank Schmidt
   16. Soo Jung Cho
   17. Jan Krumsiek

   Reviewed by ScreenIT

5. Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination

   This article has 17 authors:

   1. Grace Kenny
   2. Riya Negi
   3. Sophie O'Reilly
   4. Alejandro Garcia-Leon
   5. Dana Alalwan
   6. Colette Marie Gaillard
   7. Gurvin Saini
   8. Rosana Inzitari
   9. Eoin R. Feeney
   10. Obada Yousif
   11. Aoife G Cotter
   12. Eoghan de Barra
   13. Corinna Sadlier
   14. Fiona Crispie
   15. Peter Doran
   16. Virginie Gautier
   17. Patrick W.G. Mallon

   Reviewed by ScreenIT

6. Adaptation‐Proof SARS‐CoV‐2 Vaccine Design

   This article has 11 authors:

   1. Yashavantha L. Vishweshwaraiah
   2. Brianna Hnath
   3. Brendan Rackley
   4. Jian Wang
   5. Abhinay Gontu
   6. Morgan Chandler
   7. Kirill A. Afonin
   8. Suresh V. Kuchipudi
   9. Neil Christensen
   10. Neela H. Yennawar
   11. Nikolay V. Dokholyan

   Reviewed by ScreenIT

7. Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial

   This article has 10 authors:

   1. Muhammad Raza Shah
   2. Samreen Fatima
   3. Sehrosh Naz Khan
   4. Shafi Ullah
   5. Gulshan Himani
   6. Kelvin Wan
   7. Timothy Lin
   8. Johnson Y. N. Lau
   9. Qingquan Liu
   10. Dennis S. C. Lam

   Reviewed by ScreenIT

8. United States’ political climates and the spread of SARS-2-COVID-19 during 2020

   This article has 3 authors:

   1. Felicia Pratto
   2. Andrew Cortopassi
   3. Natasza Marrouch

   Reviewed by ScreenIT

9. Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India

   This article has 14 authors:

   1. Puneet Misra
   2. Shashi Kant
   3. Randeep Guleria
   4. Sanjay K. Rai
   5. Abhishek Jaiswal
   6. Suprakash Mandal
   7. Guruprasad R. Medigeshi
   8. Mohammad Ahmad
   9. Anisur Rahman
   10. Meenu Sangral
   11. Kapil Yadav
   12. Mohan Bairwa
   13. Partha Haldar
   14. Parveen Kumar

   Reviewed by ScreenIT

10. Variation in the ACE2 receptor has limited utility for SARS-CoV-2 host prediction

    This article has 5 authors:

    1. Nardus Mollentze
    2. Deborah Keen
    3. Uuriintuya Munkhbayar
    4. Roman Biek
    5. Daniel G Streicker

    This article has been curated by 1 group:

    • Curated by eLife

      Evaluation Summary:

      This important study shows that methods currently used to predict which animals species might be at risk of infection by SARS-CoV-2, by looking at features of the host cell receptor the virus binds to, are fundamentally flawed, with exceptionally strong support for this conclusion. Much work on the potential host range of SARS-CoV-2 has focused on measuring the susceptibility of different species' ACE2 receptors to sarbecovirus entry and extending predictions to other unmeasured species based on ACE2 sequence features. Mollentze and colleagues show that ACE2 sequences are not more than a proxy for generic species relationships. In other words, species phylogeny alone can provide equivalent predictive power, allowing for predictions of mammalian susceptibility to sarbecovirus infection for the many species for which ACE2 sequences are not known yet.

      (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. Reviewer #1 agreed to share their name with the authors.)

    Reviewed by eLife, ScreenIT